Exactly, I don't see anything of substance in this news.....you can't even begin to compare this with GERN....this is nothing but a B.S. news release
- Human Genetic Variations Associated With Mutations Responsible For Human
Disease And Drug Responses --
BOSTON, Nov. 18 /PRNewswire/ -- CuraGen Corporation (Nasdaq: CRGN) announced today that through its proprietary SeqCalling(TM) process, it has discovered greater than 60,000 human genetic variations that may be responsible for the development of certain diseases. These single nucleotide polymorphisms (cSNPs) are variations in DNA that have accumulated over time in the general
population. Recently, cSNPs have become of increasing interest to
scientists because they are believed to be useful markers in the
identification of disease genes and genetic differences which may determine the response of a patient to disease and to drug treatment.
Richard Lifton, M.D., Ph.D., Howard Hughes Medical Institute Investigator and Professor at Yale University School of Medicine, said, "SNPs are the most frequent type of genetic variation found in the human genome. Although most SNPs are found outside expressed genes, cSNPs are found in coding regions of genes and may provide important predictions about responses to drugs and disease predisposition.(1) Currently, there are approximately 5,000 publicly known SNPs and these were derived from random genomic DNA. Therefore, by identifying vast numbers of cSNPs, CuraGen is well-positioned for discovering key variations associated with specific human diseases and
drug responses."
Gregory T. Went, Ph.D., Executive Vice President of CuraGen stated, "By creating a high density cSNP map, we are further expanding our genomics capabilities enabling us and our partners to identify critical disease and response genes. Ultimately, by incorporating this cSNP information into our integrated genomics process suite, we hope to establish clear connections between cSNPs, disease pathways and therapeutic intervention which may accelerate our internal and collaborative product discovery and development efforts."
Speaking today at the Cambridge Healthtech Institute Conference entitled: Implications of Human Genetic Variation: SNPs, Polymorphisms, Diseases & Treatment, Richard Shimkets, Ph.D., Senior Research Scientist at CuraGen emphasized that variations between individuals caused by changes in DNA sequences are of particular interest because they have the potential to be directly involved in common disease traits. Dr. Shimkets noted, "It is currently believed that there are approximately 3 million SNPs in the human genome, and 200,000 of these are anticipated to be within the coding regions
of genes. Of these cSNPs, about 10% will significantly affect protein sequence,(2) and a fraction of these may determine disease predisposition and drug response. CuraGen's goal is to construct a high density cSNP map of the expressed human genome and use this cSNP information to better understand disease and treatment options."
CuraGen Corporation is revolutionizing the discovery and development of life science products through the systematic application of genomics. CuraGen's fully-integrated genomics technologies, processes, and information systems are designed to rapidly generate comprehensive information about gene expression, biological pathways, and potential products that affect these
pathways, each on a scale not previously undertaken. CuraGen is
headquartered in New Haven, CT, with additional facilities in Branford, CT, and greater- Gainesville, FL. The Company employs over 280 people. Additional Company information is available at www.curagen.com.This release may contain forward-looking statements that are subject to certain risks and uncertainties, including statements regarding the expected effects of the Company's technology. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward- looking statements as a result of various factors, including, but not limited to, the following: the Company's early stage of development, technological uncertainty and product development risks, uncertainty of additional funding, reliance on research collaborations, competition, the Company's ability to protect its patents and proprietary rights and
uncertainties relating to commercialization rights.
/CONTACT: Gregory T. Went, Ph.D., Executive Vice President of CuraGen
Corporation, 203-401-3330, or Marcia A. Kean or Lucy Morrison of Feinstein
Kean Partners Inc., 617-577-8110/
Key points,,
(1) Currently, there are approximately 5,000 publicly known SNPs and these were derived from random genomic DNA.
Translation-- similar findings have ALREADY been made and are PUBLIC knowledge
(2) and a fraction of these may determine disease predisposition and drug response. NOTE--may determine-- Translation- THEY HAVE NO F__KING IDEA |
